FDA ad­comm votes nar­row­ly against Veru's Covid drug, cit­ing un­cer­tain­ties amid mor­tal­i­ty ben­e­fit in small tri­al

The FDA’s Pul­monary-Al­ler­gy Drugs Ad­vi­so­ry Com­mit­tee on Wednes­day vot­ed 8-5 against Veru’s re­pur­posed can­cer drug, sabiz­ab­u­lin, as a treat­ment for cer­tain hos­pi­tal­ized adults with Covid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER